Reactions Weekly

, Volume 1212, Issue 1, pp 2–2 | Cite as

BioAlliance Pharma has suspended the doxorubicin Transdrug® phase II/III trial

Media release
  • 11 Downloads

Keywords

Public Health Adverse Event Doxorubicin Initial Data Clinical Benefit 

REFERENCE

  1. 1.
    BioAlliance Pharma SA.BioAlliance Pharma Suspends the Phase II/III Trial of Doxorubicin Transdrug (Rm) In Primary Liver Cancer, Following Advice from the Drug Safety Monitoring Board and the Steering Committee. Media Release: 16 Jul 2008. Available from: URL: http://www.bioalliancepharma.com

Copyright information

© Adis International limited or Adis Data Information BV 2008

Personalised recommendations